



BIONETICS

Mutagenic Evaluation of Compound FDA 75-61
Final report 10/29/76

Sodium Propionate N. F., F. C. C.

MUTAGENICITY EVALUATION

OF

SODIUM PROPIONATE

N. F., F. C. C.

FDA 75-61

FINAL REPORT

H24

5516 Nicholson Lane
Kensington, Maryland
20795

H24

MUTAGENICITY EVALUATION

OF

SODIUM PROPIONATE

N.F., F.C.C.

FDA 75-61

FINAL REPORT

SUBMITTED TO

FOOD AND DRUG ADMINISTRATION
DEPARTMENT OF HEALTH, EDUCATION AND WELFARE
5600 FISHERS LANE
ROCKVILLE, MARYLAND

SUBMITTED BY

LITTON BIONETICS, INC.
5516 NICHOLSON LANE
KENSINGTON, MARYLAND 20795

LBI PROJECT NO. 2672

OCTOBER 29, 1976



BIONETICS

TABLE OF CONTENTS

	Page No.
EVALUATION SUMMARY.....	1
I. <u>OBJECTIVE</u>	2
II. <u>MATERIALS</u>	2
A. Test Compound.....	2
B. Indicator Microorganisms.....	2
C. Reaction Mixture.....	2
D. Tissue Homogenates and Supernatants.....	3
E. Positive Control Compounds.....	3
III. <u>METHODS</u>	3
A. Toxicity.....	3
B. Plate Tests.....	4
C. Suspension Tests.....	4
D. Preparation of Tissue Homogenates and 9,000 x g Cell Fractions.....	5
E. Data Recording and Reporting.....	5
IV. <u>RESULTS SECTION</u>	
A. Solubility Properties of the Test Compound.....	6
B. Toxicity and Dosage Determinations for the Test Compound.....	6
C. Suspension Assay Results.....	7
D. Plate Assay Results.....	14
V. <u>SUMMARY OF TEST RESULTS</u>	10
VI. <u>INTERPRETATION OF RESULTS AND CONCLUSIONS</u>	15
VII. <u>EXPLANATION OF EVALUATION PROCEDURES FOR PLATE ASSAYS</u>	16
VIII. <u>EXPLANATION OF EVALUATION PROCEDURES FOR SUSPENSION ASSAYS</u>	18
APPENDIX - Tabulation of Data.....	A-1



BIONETICS

Litton

EVALUATION SUMMARY

The test compound Sodium Propionate N.F., F.C.C., FDA 75-61, 000137406, did not exhibit mutagenic activity in any of the assays employed in these studies.



BIONETICS

DATE: October 29, 1976

SPONSOR: U.S. Food and Drug Administration

SUBJECT: Evaluation of Test Compound Sodium Propionate N.F., F.C.C., FDA 75-61

I. OBJECTIVE

The objective of this study was to evaluate the test compound for genetic activity in microbial assays with and without the addition of mammalian metabolic activation preparations.

II. MATERIALS

A. Test Compound

1. Date Received: September 3, 1976
2. Description: white powder

B. Indicator Microorganisms

The following strains of indicator microorganisms were used in the evaluation:

Yeast Strain: Saccharomyces cerevisiae, strain D4

Bacteria Strains: Salmonella typhimurium, strains TA-1535
TA-1537
TA-1538
TA-98
TA-100

C. Reaction Mixture

The following reaction mixture was employed in the activation tests:

<u>Component</u>	<u>Final Concentration/ml</u>
1. TPN (sodium salt)	4 μ moles
2. Glucose-6-Phosphate	5 μ moles
3. Sodium Phosphate (dibasic) pH 7.4	100 μ moles
4. $MgCl_2$	8 μ moles
5. KCl	33 μ moles
6. Homogenate fraction equivalent to 25 mg of wet tissue.	

D. Tissue Homogenates and Supernatants

The tissue homogenates and 9,000 x g supernatants were prepared from tissues of the following mammalian species: Mouse - ICR random bred adult males; rat - Sprague-Dawley adult males; and monkey - Macaca mulatta adult males.

E. Positive Control Compounds

Table 1 lists chemicals for positive controls in the direct and activation assays.

TABLE 1
POSITIVE CONTROLS USED IN DIRECT AND ACTIVATION ASSAYS

<u>Assay</u>	<u>Chemical</u> ^a	<u>Solvent</u>	<u>Probable Mutagenic Specificity</u>
Nonactivation	Methylnitrosoguanidine	Water or saline	BPS ^b
	Ethylmethanesulfonate	Water or saline	BPS ^b
	2-Nitrofluorene	Dimethylsulfoxide ^c	FS ^b
	Quinacrine mustard	Water or saline	FS ^b
Activation	Dimethylnitrosamine	Water or saline	BPS ^b
	2-Acetylaminofluorene	Dimethylsulfoxide ^c	FS ^b
	8-Aminoquinoline	Dimethylsulfoxide ^c	FS ^b
	2-Aminoanthracene	Dimethylsulfoxide ^c	BPS ^b

- ^a Concentrations given in the Results Section
^b BPS = base-pair substitution; FS = frameshift
^c Previously shown to be non-mutagenic

III. METHODS

A. Toxicity

The solubility, toxicity and doses for the test chemical were determined prior to screening.

The test chemical was tested for toxicity against specific indicator strains over a range of doses to determine the 50% survival dose. Bacteria were tested in phosphate buffer, pH 7.4, for one hour at 37°C on a shaker. Yeasts were tested in phosphate buffer, pH 7.4, for four hours at 30°C on a shaker. The 50% survival concentrations and the 1/4 and 1/2 50% doses calculated.

If no toxicity was obtained for the chemical with a given strain, then a maximum dose of 5% (w/v) was used.

Unless otherwise specified, the doses calculated for the tests in buffer were applied to the activation tests. The solubility of the test chemical under treatment conditions is stated in the Results Section.



BIONETICS

Litton

B. Plate Tests (Overlay Method)

Approximately 10^8 cells from an overnight culture of each indicator strain were added to test tubes containing 2.0 ml of molten agar supplemented with biotin and a trace of histidine. For nonactivation tests, the three dose levels of the test compound were added to the contents of the appropriate tubes and poured over the surfaces of selective agar plates. In activation tests 0.5 ml of a $9,000 \times g$ tissue supernatant and required cofactors (core reaction mixture) were added to the overlay tubes. Three dose levels of the test chemical were added to the appropriate tubes, which were then mixed and the contents poured over the surface of a minimal agar (selective medium) plate and allowed to solidify. The plates were incubated for 48 to 72 hours at 37°C , and scored for the number of colonies growing on each plate. The concentrations of all chemicals are given in the Results Section. Positive and solvent controls using positive compounds that are active directly and those that require metabolic activation were run with each assay.

C. Suspension Tests

1. Nonactivation

Bacteria and yeast cultures of the indicator organisms were grown in complete broth, washed and resuspended in 0.9% saline to densities of 1×10^{10} cells/ml and 5×10^9 cells/ml, respectively. This constituted the working stock for tests of a group of test chemicals and their respective controls. Tests were conducted in plastic, 24-well tissue culture plates (Linbro). Cells plus appropriate volume(s) of the test chemical were added to the wells to give a final volume of 1.5 ml. The solvent replaced the test chemical in the negative controls. Treatment was at 30°C for four hours for yeast tests and at 37°C for one hour for bacterial tests. All flasks were shaken during treatment. Following treatment, the plates were set on ice. Aliquots of cells were removed, diluted in sterile saline (4°C) and plated on the appropriate complete media. Undiluted samples from flasks containing the bacteria were plated on minimal selective medium in reversion experiments. Samples from a 10^{-1} dilution of treated cells were plated on the selected media for enumeration of gene conversion with strain D4. Bacterial plates were scored after incubation for 48 hours at 37°C . The yeast plates were incubated at 30°C for 3-5 days before scoring.

2. Activation

Bacteria and yeast cells were grown and prepared as described in the nonactivation tests. Measured amounts of the test and control chemicals plus 0.25 ml of the stock-cell suspension were added to wells of the Linbro plate containing the appropriate tissue fraction and reaction mixture. All flasks (bacteria and yeast) were incubated at 37°C with shaking. The treatment times as well as the dilutions, plating procedures and scoring of the plates were the same as described for nonactivation tests.



BIONETICS

D. Preparation of Tissue Homogenates and 9,000 x g Cell Fractions

Male animals (except monkeys) sufficient to provide the necessary quantities of tissues were killed by cranial blow, decapitated and bled. Monkey tissues were obtained from freshly killed and bled male rhesus monkeys. Organs were immediately dissected from the animals using aseptic techniques and placed in ice-cold 0.15 M KCl. Upon collection of the desired quantity of organs, they were washed twice with fresh KCl and completely homogenized with a motor-driven homogenizing unit at 4°C. The whole organ homogenate obtained from this step was divided into two samples. One sample was frozen at -80°C and the other was centrifuged for 20 minutes at 9,000 x g in a refrigerated centrifuge. The supernatant from the centrifuged sample was retained and frozen at -80°C. These two frozen samples were used for the activation studies. Protein and P-448 determinations were made for each lot of homogenate.

E. Data Recording and Reporting

1. Suspension assays

Following the specified incubation periods all population plates were scored by an automatic colony counter and the results from each plate of a set were recorded, in ink, on data processing forms. All minimal or other types of selective media plates were hand scored and the results recorded along with the respective population data. Other relevant experimental data were recorded on experimental definition forms. For bacteria strains the number of colonies recorded from either the population or selective plates represents that number in 1 ml of test suspension plated. The numbers recorded for the yeast strain D4 represent the number in 0.5 ml of test suspension plated. The data were then processed and printed from a computer program. All raw data sheets are dated and signed by the responsible technician.

2. Plate test assays

The numbers of colonies on each plate were counted and recorded on printed forms. These raw data were entered into a computer program designed to print out all data by test. The data are presented as revertants per plate for each indicator strain employed in the assay. The positive and solvent controls are provided as reference points.

IV. RESULTS SECTION

A. Solubility Properties of the Test Compound

1. Name or code designation of the test compound: 000137-40-6
2. Test solvent: Saline
3. Solubility of the test compound under treatment conditions:
Soluble
4. Additional comments: White powder

B. Toxicity and Dosage Determinations for the Test Compound

1. Test date for toxicity determination: September 8, 1976
2. The 50% survival level was determined for bacteria and yeast indicator organisms by conducting survival curves with the test compound at the following concentrations:

Percent Concentration (w/v or v/v)

5.0
0.5
0.05
0.005
0.0005

3. Concentrations of the test compound used in the mutagenicity tests:

<u>Test Doses</u>	<u>Percent Concentration</u>	
	<u>Bacteria</u>	<u>Yeast</u>
1/4 50% Survival	0.625	1.25
1/2 50% Survival	1.250	2.50
50% Survival	2.500	5.00



BIONETICS

C. Suspension Assay Results

The suspension test results for the test compound are summarized in the following six tables. The values presented in these tables are the calculated mutation frequencies for each control and experimental test point. The first table of the suspension set presents the results for the nonactivation assays, and the second through the fourth table of the suspension set presents the results for the activation assays. The fifth table shows the results of the nonactivation plate test and the sixth table shows the results of the activation plate test. A listing of computer codes and abbreviations is included for reference. Tabulation of all raw data is provided in the Appendix.



BIONETICS

DATA TABLE TERMS AND ABBREVIATIONS

ABBREVIATION OR TERM	DEFINITION OR EXPLANATION
COMPOUND	Client designated compound number appears in this column.
TEST CODES	<p> NAN = Nonactivation: Solvent Control NAP = Nonactivation: Positive Control NA1 = Nonactivation: Test Compound Dose 1 NA2, etc. = Reflects the other dose level(s) </p> <p> A+C = Negative Chemical Control for ACP A-C = Activation: Solvent Control ALI or A+T = Activation: Homogenate Control (Liver) ALU = Activation: Homogenate Control (Lung) ACP = Activation: Positive Control ACT = Activation Test </p> <p> LI = Liver Tissue Activation Fraction LU = Lung Tissue Activation Fraction KI = Kidney Tissue Activation Fraction TE = Testes Tissue Activation Fraction 1,2, etc. = Dose Levels </p>
CONCENTRATION	<p>All test compound dose levels are expressed as a whole number followed by an exponent (negative) identified by the appropriate units.</p> <p>Example: 0025-2PCT = 0.25 percent concentration</p>
POPU	Total number of viable cells in the plating sample raised to some exponent printed directly below the abbreviation (i.e., EP + 6 = $\times 10^6$).
MUT 1	Total number of mutants or convertants obtained from the sample plated raised to some exponent printed directly below the abbreviation (i.e., EP + 0 = 10^0). For strain D4, MUT 1 represents the number of ADE+ convertants.
MUT 2	Only used for strain D4 and represents the number of TRY+ convertants in the plated sample.
FREQ 1	The calculated mutation or gene conversion frequency times the negative exponent written directly below. For strain D4, FREQ 1 represents the ADE+ value.
FREQ 2	Only used for strain D4 and represents the TRY+ conversion frequency.
CONTAM	Presence of contamination on any plates.



BIONETICS

DATA TABLE TERMS AND ABBREVIATIONS (continued)

ABBREVIATION OR TERM	DEFINITION OR EXPLANATION
AAF	2-Acetylaminofluorene
DMSO	Dimethylsulfoxide
DMN	Dimethylnitrosamine
EMS	Ethylmethanesulfonate
QM	Quinacrine Mustard
NF	Nitrofluorene
ANTH	2-Amino Anthracene
AMQ	8-Amino Quinoline
SPECIES	Animal Strains
SPRDAW	Sprague Dawley Rats
ICRFLO	Flow ICR Random Bred Mice
RHESUS	Rhesus Monkey (<u>Macaca mulatta</u>)
MIXEDB	Dog, Mixed Breed
NEWZEA	New Zealand White Rabbit
UG	Microgram
UM	Micromole
ADE	Adenine
TRY	Tryptophan

LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
REPORT EXR34

COMPOUND FREQUENCY SUMMARY REPORT 10/27/76

SPECIES /NONACTIVATION COMPOUND 000137406

TEST	ORG	TA100 HIS EX-8	TA1535 HIS EX-8	TA1537 HIS EX-8	TA1538 HIS EX-8	TA1538 HIS EX-8	TA98 HIS EX-8	0000D4 ADE EX-5	0000D4 TRY EX-5	
NAN		66.63	18.29	14.48	1.21	4.11	13.86	22.36	9.75	CONTROLS
NAP		729.93	4938.27	95.62	143.90		820.41	68.71	38.10	
NA1		96.79	17.07	6.72	2.57	3.16	13.66	20.87	9.10	TEST DATA
NA2		83.38	28.57	6.63	2.41		8.50	24.12	10.22	
NA3		74.66	11.11	8.82	1.35		4.95	19.93	9.93	

LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
REPORT EXR34

COMPOUND FREQUENCY SUMMARY REPORT 10/27/76

SPECIES ICRFLO/MOUSE

COMPOUND 000137406

TEST	ORG	TA100 HIS EX-8	TA1535 HIS EX-8	TA1535 HIS EX-8	TA1537 HIS EX-8	TA1538 HIS EX-8	TA1538 HIS EX-8	TA98 HIS EX-8	TA98 HIS EX-8	0000D4 ADE EX-5	0000D4 TRY EX-5	
ACT	A+C	20.58	7.58		2.69	29.04		4.72		23.27	8.14	
ACT	A-C	22.30	5.57		5.85	28.54		3.09		26.15	7.98	
ACT	ALI	24.42	6.44	4.74	6.95	49.71	7.94	9.94		26.53	8.68	NEGATIVE CONTROL
ACT	ALU	21.77	7.57	3.44	3.65	25.54	12.18	5.41	8.65	28.89	8.63	
ACT	PLI	70.14	136.26		142.77	202.67		106.30		67.69	27.36	POSITIVE CONTROL
ACT	PLU	22.31	27.00		2.14	38.36		110.39		32.40	11.43	
ACT	LI1	47.37	9.25		7.81	26.20		21.81		28.83	9.22	TEST DATA
ACT	LI2	44.62	18.07	3.40	6.71	30.32		23.97		27.46	6.84	
ACT	LI3	24.70	21.81		3.03	27.22		14.23		26.19	8.19	
ACT	LU1	30.13	9.86		14.46	22.20		49.50	20.23	24.39	7.58	
ACT	LU2	28.69	16.13		11.01	19.32		9.51		18.21	8.25	
ACT	LU3	27.38	8.07		11.43	71.37	9.70	15.31	11.87	22.91	9.95	

LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
REPORT EXR34

COMPOUND FREQUENCY SUMMARY REPORT 10/27/76

SPECIES SPRDAW/RAT

COMPOUND 000137406

TEST	ORG	TA100 HIS EX-8	TA1535 HIS EX-8	TA1537 HIS EX-8	TA1538 HIS EX-8	TA98 HIS EX-8	0000D4 ADE EX-5	0000D4 TRY EX-5	
ACT	A+C	20.72	10.78	4.17	4.92	15.89	43.00	21.56	
ACT	A-C	25.83	10.16	2.65	4.12	12.44	51.25	20.37	
ACT	ALI	31.45	13.54	3.74	18.45	11.62	41.81	26.41	NEGATIVE CONTROL
ACT	ALU	27.04	12.64	2.11	7.49	20.06	39.12	21.07	
ACT	PLI	61.73	246.86	122.50	218.59	84.05	79.89	60.49	POSITIVE CONTROL
ACT	PLU	28.22	13.97	1.37	273.20	24.85	40.92	22.52	
ACT	L11	40.22	9.68	3.12	8.17	22.97	49.31	16.12	TEST DATA
ACT	L12	38.52	10.09	3.16	12.95	21.28	51.33	19.81	
ACT	L13	29.13	17.17	3.26	16.76	23.98	42.04	15.18	
ACT	LU1	43.57	4.81	2.38	4.43	20.79	52.28	14.00	
ACT	LU2	46.09	4.90	3.19	12.16	16.28	43.94	12.89	
ACT	LU3	32.00	5.90	2.73	13.51	18.25	49.92	15.17	

LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
REPORT EXR34

COMPOUND FREQUENCY SUMMARY REPORT 10/27/76

SPECIES RHESUS/MONKEY

COMPOUND 000137406

TEST	ORG	TA100 HIS EX-8	TA1535 HIS EX-8	TA1537 HIS EX-8	TA1538 HIS EX-8	TA98 HIS EX-8	0000D4 ADE EX-5	0000D4 TRY EX-5
ACT	A+C	26.73	7.45	11.79	3.31	26.43	13.21	7.50
ACT	A-C	25.84	9.64	7.98	6.21	27.12	16.19	7.53
ACT	ALI	30.06	6.89	18.45	10.77	56.55	15.71	7.72
ACT	ALU	28.62	7.57	22.19	3.79	61.49	8.72	5.72
ACT	PLI	60.22	58.15	3.07	580.84	88.51	67.41	24.55
ACT	PLU	30.95	8.82	13.13	3.86	42.92	12.93	6.12
ACT	LI1	42.64	7.30	14.55	11.63	36.01	14.06	6.71
ACT	LI2	34.50	6.29	21.19	10.99	29.25	15.62	6.81
ACT	LI3	29.30	6.42	15.81	13.43	47.38	14.77	5.88
ACT	LU1	43.28	6.51	15.13	10.98	24.87	13.84	7.39
ACT	LU2	27.16	5.66	19.70	10.31	28.75	11.83	5.59
ACT	LU3	33.08	7.82	16.48	14.79	24.15	11.74	5.56

NEGATIVE CONTROL

POSITIVE CONTROL

TEST DATA

SUMMARY OF TEST RESULTS

PLATE TESTS

A. NAME OR CODE DESIGNATION OF THE TEST COMPOUND: 000137406
 B. TEST DATE: OCT. 12, 1976

TEST	SPECIES	ISSUE	B E V E R T A N I S P E R P L A T E									
			IA-1535		IA-1537		IA-1538		IA-98		IA-100	
			1	2	1	2	1	2	1	2	1	2
1. NON-ACTIVATION												
SOLVENT CONTROL*	---	---	31	23	31	19	19	18	22	21	201	248
POSITIVE CONTROL**	---	---	>1000	>1000	895	461	>1000	>1000	>1000	>1000	>1000	>1000
TEST 2.50000 %	---	---	28	26	26	26	6	12	10	20	171	160
1.25000 %	---	---	35	23	31	24	4	11	15	24	176	163
0.62500 %	---	---	25	22	39	36	10	13	26	20	253	276
2. ACTIVATION												
SOLVENT CONTROL*	MOUSE	LIVER	25	40	20	12	22	23	24	19	111	123
	RAT	LIVER	20	20	14	11	32	28	40	59	89	77
	MONKEY	LIVER	16	41	12	6	22	36	51	60	57	71
POSITIVE CONTROL***	MOUSE	LIVER	202	154	303	516	>1000	>1000	167	129	123	100
	RAT	LIVER	94	91	>1000	127	462	500	239	173	154	181
	MONKEY	LIVER	513	375	80	119	>1000	>1000	142	183	167	285
TEST 2.50000 %	MOUSE	LIVER	18	8	15	6	18	25	25	22	134	130
1.25000 %	MOUSE	LIVER	27	20	12	21	15	9	13	13	137	133
0.62500 %	MOUSE	LIVER	36	35	11	17	20	9	15	22	133	150
2.50000 %	RAT	LIVER	22	13	10	8	14	29	52	29	71	48
1.25000 %	RAT	LIVER	10	11	12	9	15	6	54	49	73	74
0.62500 %	RAT	LIVER	22	20	11	19	11	20	54	54	72	79
2.50000 %	MONKEY	LIVER	53	32	15	7	17	11	46	37	64	67
1.25000 %	MONKEY	LIVER	41	32	14	5	19	4	45	57	74	76
0.62500 %	MONKEY	LIVER	33	32	6	11	15	7	41	66	67	88

* NON-ACTIVATION ASSAYS CONSIST OF THE CELLS PLUS THE TEST COMPOUND VEHICLE (SOLVENT). FOR ACTIVATION ASSAYS, THE OVERLAY CONTAINS THE ACTIVATION SYSTEM PLUS THE TEST COMPOUND VEHICLE.

** TA-1535 MNNG 2 UG/PLATE
 TA-1537 QM 20 UG/PLATE
 TA-1538 NF 100 UG/PLATE
 TA-98 NF 100 UG/PLATE
 TA-100 MNNG 2 UG/PLATE

*** TA-1535 ANTH 100 UG/PLATE
 TA-1537 AMQ 100 UG/PLATE
 TA-1538 AAF 100 UG/PLATE
 TA-98 AAF 100 UG/PLATE
 TA-100 ANTH 100 UG/PLATE

NOTE: CONCENTRATIONS ARE GIVEN IN MICROLITERS(UL) OR MICROGRAMS(UG) PER PLATE.

VI. INTERPRETATION OF RESULTS AND CONCLUSIONS

Compound: Sodium Propionate N.F., F.C.C., FDA 75-61, 000137406.

A. Salmonella typhimurium

1. Plate Tests

The results of these tests were all negative.

2. Nonactivation Suspension Tests

The results of these tests were all negative. The NA₁ dose with TA-1538 was repeated because of low mutant counts. The repeat test was negative.

3. Activation Suspension Tests

The results of these tests were all negative. The LI₂ dose with TA-1535, the LU₃ dose with TA-1538 and LU₁ and LU₃ doses with TA-98 using mouse tissue were repeated because of increased mutant frequency. The repeat tests were negative.

B. Saccharomyces cerevisiae

1. Nonactivation Suspension Tests

The results of these tests were negative.

2. Activation Suspension Tests

The results of these tests were negative.

C. Conclusions

The test compound Sodium Propionate N.F., F.C.C., FDA 75-61, 000137406, did not exhibit mutagenic activity in any of the assays employed in these studies.

Submitted by:

David J. Brusick, Ph.D. Date 10/29/70
Director
Department of Genetics

Reviewed by:

Robert J. Weir, Ph.D. Date 10/29/70
Vice President

VII. EXPLANATION OF EVALUATION PROCEDURES FOR PLATE ASSAYS

Plate test data consist of direct revertant colony counts obtained from a set of selective agar plates seeded with populations of mutant cells suspended in a semisolid overlay. Because the test chemical and cells are incubated in the overlay for 2-3 days, and a few cell divisions occur during the incubation period, the test is semiquantitative in nature. Although these features of the assay reduce the quantitation of results, they provide certain advantages not contained in a quantitative suspension test.

- The small number of cell divisions permits potential mutagens to act on replicating DNA which is often more sensitive than non-replicating DNA.
- The combined incubation of the compound and the cells in the overlay permit constant exposure of the indicator cells for 2-3 days.

A. Surviving Populations

Plate test procedures do not permit exact quantitation of the number of cells surviving chemical treatment. At low concentrations of the test chemical, the surviving population on the treatment plates is essentially the same as the negative control plate. At high concentrations, the surviving population is usually reduced by some fraction. Our protocol normally employs dose levels that are selected such that the highest dose will show slight toxicity (as determined by subjective criteria) and several doses ranging down 1 to 2 logs lower.

B. Dose Response Phenomena

The demonstration of dose-related increases in mutant counts is an important criterion in establishing mutagenicity. Factors which may modify dose response results for a mutagen would be the selection of doses that are too low (usually mutagenicity and toxicity are related). If the highest dose is far lower than a toxic concentration, no increases may be observed over the dose range selected. Conversely, if the lowest dose employed is highly cytotoxic, the test chemical may kill any mutants that are induced and the compound will not appear to be mutagenic.

C. Control Tests

Positive and negative control assays are conducted with each experiment and consist of direct acting mutagens for nonactivation assays and mutagens that require metabolic biotransformation in activation assays. Negative controls consist of the test compound solvent in the overlay agar with the other essential components. The negative control plate for each strain gives a reference point to which the test data are compared. The positive control assay is conducted to demonstrate that the test systems are functional with known mutagens.



BIONETICS

D. Evaluation Criteria for Ames Assay

Because the procedures used to evaluate the mutagenicity of the test chemical are semiquantitative, the criteria used to determine positive effects are inherently subjective and based primarily on a historical data base. Most data sets are evaluated using the following criteria:

1. Strains TA-1535, TA-1537, and TA-1538

If the solvent control value is within the normal range, a chemical which produces a positive dose response over three concentrations with the lowest increase equal to twice the solvent control value is considered to be mutagenic.

2. Strains TA-98, TA-100, and D4

If the solvent control value is within the normal range, a chemical which produces a positive dose response over three concentrations with the highest increase equal to twice the solvent control value for TA-100 and two to three times the solvent control value for strains TA-98 and D4 is considered to be mutagenic. For these strains, the dose response increase should start at approximately the solvent control value.

3. Pattern

Because TA-1535 and TA-100 were both derived from the same parental strain (G-46) and because TA-1538 and TA-98 were both derived from the same parental strain (D3052), there is a built-in redundancy in the microbial assay. In general the two strains of a set respond to the same mutagen and such a pattern is sought. It is also anticipated that if a given strain, e.g. TA-1537, responds to a mutagen in nonactivation tests it will generally do so in activation tests. (The converse of this relationship is not expected.) While similar response patterns are not required for all mutagens, they can be used to enhance the reliability of an evaluation decision.

4. Reproducibility

If a chemical produces a response in a single test which cannot be reproduced in one or more additional runs, the initial positive test data loses significance.

The preceding criteria are not absolute and other extenuating factors may enter into a final evaluation decision. However, these criteria are applied to the majority of situations and are presented to aid those individuals not familiar with this procedure. As the data base is increased, the criteria for evaluation can be more firmly established.

VIII. EXPLANATION OF EVALUATION PROCEDURES FOR SUSPENSION ASSAYS

Data obtained from mutagenicity tests are evaluated on a test by test basis followed by an examination of the total response pattern using all the data. To facilitate this type of evaluation, we have prepared two separate formats in which data are processed. The first is the Compound Summary Backup Detail Sheet, which details the essential raw data from each experiment showing surviving population counts, total mutant or revertant counts, as well as, calculated mutation frequencies. This format permits close examination of each set of test data. The following considerations are part of any assessment.

A. Surviving Population Counts

A certain level of chemically-induced toxicity is anticipated, but occasionally isolated tests or groups of tests show very low (<25%) survival compared to the tissue controls. Such isolated decreases may result from improper dilution procedures or defective growth media and decrease confidence in the calculated mutation frequencies especially if the total mutant counts appear unaffected. Data of this type are generally unacceptable and these experiments are routinely repeated at a lower dose level to reduce killing and increase confidence in the nature of the response.

B. Total Mutant Counts

For nonmutagens, the mutant/surviving population ratio should be roughly equivalent for each test point in a given experiment. If the cell number drops in response to killing, the mutant number should decrease proportionately. A mutagenic chemical, however, will produce an altered mutant/surviving population ratio. Mutant numbers as well as calculated frequencies are compared to the negative control data. In certain instances, the mutant frequencies will increase with little or no change in the absolute number of mutants especially where the test chemical is toxic. Data of this type, although not necessarily aberrant, or even rare, must be viewed with special care to ensure that the increased frequencies were not the result of selective toxicity of the test chemical for the his⁻ cells. This phenomenon, referred to as selection, can lead to erroneous conclusions. Thus we attempt to keep the surviving population of cells high and look for positive responses that show increases in both numbers of mutants and mutation frequencies. Again, occasional isolated fluctuations in mutant counts are found that can be attributed to improper pipetting or media contamination. These fluctuations are usually easy to identify by inspection of the other data points in the experiment which will be negative.

C. Dose Response Phenomena

Dose-related increases in mutants and mutation frequencies are the most convincing data to have in assessing mutagenic activity of chemicals. In some cases, however, dose-related increases are not observed for mutagens. This depends considerably on the dose levels selected. The figure on the following page illustrates how one might obtain various types of dose-related responses by a mutagen based solely on dose selection. It also emphasizes the need to keep dose levels within a relatively low range of toxicity so that data are consistently on the uphill side of the hypothetical curve.

D. Control Tests

Positive and negative control tests are conducted with each experiment and consist of direct acting positive agents for nonactivation assays and chemicals that require metabolic transformation for activation assays. In nonactivation assays, the NAN control contain the test chemical solvent plus cells, but no chemical, and is used as a reference to assess the level of response obtained in the various tests. It is not possible at this time to put precise cut-off points where negative responses become positive responses. A statistical component for our computer program is under development and will be included when available. Positive controls are only used as relative reference points and to demonstrate that the system is functioning with known mutagens. In activation assays, three types of negative controls are run: (1) A solvent control minus the chemical and minus the activation system (A-C); (2) a control plus the positive control chemical minus the activation system (A+C); and (3) a control containing the activation system and the test chemical solvent (ALI or ALU). All three controls are used collectively to assess the level of response in the various activation tests. A chemical may appear positive when compared to an A-C control but not when compared to an A+T control. The value of each of the above controls with respect to their weight in evaluation is $ALI \text{ or } ALU > A-C > A+C$.

The other data format is the Compound Frequency Summary Report sheet in which all the calculated frequencies obtained for a given compound are displayed in a table. This format permits an overview of all data. The points form a matrix of information that should present a consistent pattern. Nonmutagens should produce a matrix with data frequencies clustered around the negative control values. Occasional random high or low fluctuations are not uncommon and seldom indicate true genetic activity. Mutagenic chemicals should, on the other hand, produce a set of consistent responses that demonstrate a logical pattern. The patterns depend on the mutagenic specificity of the chemical but can be easily recognized in the Compound Frequency Summary Report format.


These mutagenicity assays are designed to optimize the probability of recognizing mutagens from nonmutagens and, in most cases, they work well. Occasionally, the data points are such that a definitive conclusion cannot be made without additional data.



BIONETICS

Litton

HYPOTHETICAL MUTATION AND TOXICITY KINETICS



HYPOTHETICAL EXPERIMENT

- (1) Dose levels 1, 2 & 3 were used
- (2) Dose levels 2, 3 & 4 were used
- (3) Dose levels 3, 4 & 5 were used

OBSERVED DOSE RESPONSE

A typical positive dose response set of data would be obtained.

The intermediate dose level shows a higher mutation frequency than both the low dose and the high dose.

Here an inverted dose response would be observed with the highest dose level showing the lowest response.

STANDARD OPERATING PROCEDURES

To ensure an accurate and reliable mutagenicity testing program, LBI instituted the following procedures:

- The test compound was registered in a bound log book recording the date of receipt, complete client identification, physical description and LBI code number.
- Complete records of weights and dilutions associated with the testing of the submitted material were entered into a bound notebook.
- Raw data information was recorded on special printed forms that were dated and initialed by the individual performing the data collection at the time the observations were made. These forms were filed as permanent records.
- All animal tissue S-9 preparations used in the activation tests were taken from dated and pretested frozen lots identified by a unique number. The S-9 preparations were monitored for uniformity and the information recorded.



BIONETICS

APPENDIX
Tabulation of Data



BIONETICS

REPORT EXR33 LITTON RIONETICS MUTAGENIC ACTIVITY SYSTEM
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104		PROJECT 02468		DATE - 10/27/76			
EXPERIMENT 627205	DETECTOR TA100	SPECIES /					
COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	NAN		SOLVENT	0803	0535	66.63	0
	NAP		EMS 0.066%	0548	4000	729.93	0
000137406	NA1		0025-1 PCT.	0560	0542	96.79	0
000137406	NA2		0125-2 PCT.	0650	0542	83.38	0
000137406	NA3		0625-3 PCT.	0742	0554	74.66	0

REPORT EXR33 LITTON RIONETICS MUTAGENIC ACTIVITY SYSTEM
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104		PROJECT 02468			
EXPERIMENT 625801	DETECTOR TA1535	SPECIES	/	DATE - 10/27/76	

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	NAN		SOLVENT	0257	0047	18.29	0
	NAP		FMS 0.2%	0081	4000	4938.27	0
000137406	NA1		0025-1 PCT.	0164	0028	17.07	0
000137406	NA2		0125-2 PCT.	0189	0054	28.57	0
000137406	NA3		0625-3 PCT.	0225	0025	11.11	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
COMPOUND SUMMARY BACKUP DETAIL

		CONTRACT 22374-2104		PROJECT 02468		
EXPERIMENT 626501		DETECTOR TA1537		SPECIES /		DATE - 10/27/76

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	NAN		SOLVENT	0221	0032	14.48	0
	NAP		QM 13 UG/ML	0251	0240	95.62	0
000137406	NA1		0025-1 PCT.	0238	0016	6.72	0
000137406	NA2		0125-2 PCT.	0166	0011	6.63	0
000137406	NA3		0625-3 PCT.	0170	0015	8.82	0

REPORT EXP33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
COMPOUND SUMMARY HACKUP DETAIL

CONTRACT 22374-2104		PROJECT 02468				DATE - 10/27/76	
EXPERIMENT 626402	DETECTOR TA1538	SPECIES					
COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	NAN		SOLVENT	0911	0011	1.21	0
	NAP		NF 667 UG/ML	0410	0590	143.90	0
000137406	NA1		0025-1 PCT.	0311	0008	2.57	0
000137406	NA2		0125-2 PCT.	0415	0010	2.41	0
000137406	NA3		0625-3 PCT.	0591	0008	1.35	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
 COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104
 EXPERIMENT 626806 DETECTOR TA1538 SPECIES PROJECT 02468
 /

DATE - 10/27/76

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	NAN		SOLVENT	0365	0015	4.11	0
000137406	NA1		0025-1 PCT.	0316	0010	3.16	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104
EXPERIMENT 625905 DETECTOR TA98 SPECIES PROJECT 02468
/

DATE - 10/27/76

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	NAN		SOLVENT	0202	0028	13.86	0
	NAP		NF 667 UG/ML	0049	0402	820.41	0
000137406	NA1		0025-1 PCT.	0161	0022	13.66	0
000137406	NA2		0125-2 PCT.	0200	0017	8.50	0
000137406	NA3		0625-3 PCT.	0222	0011	4.95	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104		PROJECT 02468			
EXPERIMENT 628801	DETECTOR 000004	SPECIES	/	DATE - 10/27/76	

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+4	MUT1 EP+1	MUT2 EP+1	FREQ1 EP-5	FREQ2 EP-5	CONTAM
	NAN		SOLVENT	1118	0250	0109	22.36	9.75	0
	NAP		EMS 1.0 %	0294	0202	0112	68.71	38.10	0
000137406	NA1		0005-0 PCT.	1198	0250	0109	20.87	9.10	0
000137406	NA2		0025-1 PCT.	1194	0288	0122	24.12	10.22	0
000137406	NA3		0125-2 PCT.	1480	0295	0147	19.93	9.93	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104 PROJECT 02468
EXPERIMENT 627805 DETECTOR TA100 SPECIES ICRFLO/MOUSE DATE - 10/27/76

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		DMN 90 UM/ML	2342	0482	20.58	0
	A-C		SOLVENT	2274	0507	22.30	0
	ALI		TISSUE	2604	0636	24.42	0
	ALU		TISSUE	2104	0458	21.77	0
	ACP	LI	DMN 90 UM/ML	1400	0982	70.14	0
	ACP	LU	DMN 90 UM/ML	2506	0559	22.31	0
000137406	ACT	LI1	0025-1 PCT.	1408	0667	47.37	0
000137406	ACT	LI2	0125-2 PCT.	1524	0680	44.62	0
000137406	ACT	LI3	0625-3 PCT.	2146	0530	24.70	0
000137406	ACT	LU1	0025-1 PCT.	1434	0432	30.13	0
000137406	ACT	LU2	0125-2 PCT.	1436	0412	28.69	0
000137406	ACT	LU3	0625-3 PCT.	1662	0455	27.38	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104 PROJECT 02468
EXPERIMENT 625904 DETECTOR TA1535 SPECIES ICRFLO/MOUSE

DATE - 10/27/76

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		DMN 90 UM/ML	0488	0037	7.58	0
	A-C		SOLVENT	0539	0030	5.57	0
	ALI		TISSUE	0357	0023	6.44	0
	ALU		TISSUE	0383	0029	7.57	0
	ACP	LI	DMN 90 UM/ML	0353	0481	136.26	0
	ACP	LU	DMN 90 UM/ML	0337	0091	27.00	0
000137406	ACT	LI1	0025-1 PCT.	0519	0048	9.25	0
000137406	ACT	LI2	0125-2 PCT.	0415	0075	18.07	0
000137406	ACT	LI3	0625-3 PCT.	0376	0082	21.81	0
000137406	ACT	LU1	0025-1 PCT.	0416	0041	9.86	0
000137406	ACT	LU2	0125-2 PCT.	0310	0050	16.13	0
000137406	ACT	LU3	0625-3 PCT.	0644	0052	8.07	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104 PROJECT 02468
EXPERIMENT 626811 DETECTOR TA1535 SPECIES ICRFLO/MOUSE

DATE - 10/27/76

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	ALI		TISSUE	0949	0045	4.74	0
	ALU		TISSUE	1512	0052	3.44	0
000137406	ACT	LI2	0125-2 PCT.	1411	0048	3.40	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104 PROJECT 02468
EXPERIMENT 629301 DETECTOR TA1537 SPECIES ICRFLO/MOUSE

DATE - 10/27/76

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		AMQ 333 UG/ML	0595	0016	2.69	0
	A-C		SOLVENT	0547	0032	5.85	0
	ALI		TISSUE	0518	0036	6.95	2
	ALU		TISSUE	0548	0020	3.65	0
	ACP	LI	AMQ 333 UG/ML	0311	0444	142.77	0
	ACP	LU	AMQ 333 UG/ML	0608	0013	2.14	0
000137406	ACT	LI1	0025-1 PCT.	0589	0046	7.81	0
000137406	ACT	LI2	0125-2 PCT.	0730	0049	6.71	0
000137406	ACT	LI3	0625-3 PCT.	0760	0023	3.03	0
000137406	ACT	LU1	0025-1 PCT.	0408	0059	14.46	0
000137406	ACT	LU2	0125-2 PCT.	0454	0050	11.01	0
000137406	ACT	LU3	0625-3 PCT.	0516	0059	11.43	0

REPORT EXR33 LITTON RIONETICS MUTAGENIC ACTIVITY SYSTEM
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104 PROJECT 02468
EXPERIMENT 626001 DETECTOR TA1538 SPECIES ICRFLO/MOUSE DATE - 10/27/76

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		ANTH 67 UG/ML	0954	0277	29.04	0
	A-C		SOLVENT	0862	0246	28.54	0
	ALI		TISSUE	0523	0260	49.71	0
	ALU		TISSUE	0924	0236	25.54	0
	ACP	LI	ANTH 67 UG/ML	0449	0910	202.67	0
	ACP	LU	ANTH 67 UG/ML	0842	0323	38.36	0
000137406	ACT	LI1	0025-1 PCT.	0706	0185	26.20	0
000137406	ACT	LI2	0125-2 PCT.	0620	0188	30.32	0
000137406	ACT	LI3	0625-3 PCT.	1047	0285	27.22	0
000137406	ACT	LU1	0025-1 PCT.	0599	0133	22.20	0
000137406	ACT	LU2	0125-2 PCT.	0709	0137	19.32	0
000137406	ACT	LU3	0625-3 PCT.	0688	0491	71.37	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
COMPOUND SUMMARY HACKUP DETAIL

CONTRACT 22374-2104 PROJECT 02468
EXPERIMENT 626809 DETECTOR TA1538 SPECIES ICRFLO/MOUSE DATE - 10/27/76

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	ALI		TISSUE	0441	0035	7.94	0
	ALU		TISSUE	0238	0029	12.18	0
000137406	ACT	LU3	0625-3 PCT.	0299	0029	9.70	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104 PROJECT 02468
EXPERIMENT 627206 DETECTOR TA98 SPECIES ICRFLO/MOUSE DATE - 10/27/76

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		ANTH 67 UG/ML	0657	0031	4.72	0
	A-C		SOLVENT	1003	0031	3.09	0
	ALI		TISSUE	0714	0071	9.94	0
	ALU		TISSUE	0702	0038	5.41	0
	ACP	LI	ANTH 67 UG/ML	0603	0641	106.30	0
	ACP	LU	ANTH 67 UG/ML	0770	0850	110.39	0
000137406	ACT	LI1	0025-1 PCT.	0188	0041	21.81	0
000137406	ACT	LI2	0125-2 PCT.	0242	0058	23.97	0
000137406	ACT	LI3	0625-3 PCT.	0253	0036	14.23	0
000137406	ACT	LU1	0025-1 PCT.	0202	0100	49.50	0
000137406	ACT	LU2	0125-2 PCT.	0431	0041	9.51	0
000137406	ACT	LU3	0625-3 PCT.	0392	0060	15.31	0

REPORT EXR33 LITTON RIONETICS MUTAGENIC ACTIVITY SYSTEM
COMPOUND SUMMARY BACKUP DETAIL

		CONTRACT 22374-2104		PROJECT 02468		
EXPERIMENT 628904		DETECTOR TA98		SPECIES ICRFLO/MOUSE		DATE - 10/27/76

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	ALU		TISSUE	1225	0106	8.65	2
000137406	ACT	LU1	0025-1 PCT.	0796	0161	20.23	0
000137406	ACT	LU3	0625-3 PCT.	1087	0129	11.87	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104 PROJECT 02468
EXPERIMENT 629202 DETECTOR 0000D4 SPECIES ICRFLO/MOUSE DATE - 10/27/76

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+4	MUT1 EP+1	MUT2 EP+1	FREQ1 EP-5	FREQ2 EP-5	CONTAM
	A+C		DMN 90 UM/ML	1474	0343	0120	23.27	8.14	0
	A-C		SOLVENT	1304	0341	0104	26.15	7.98	0
	ALI		TISSUE	1244	0330	0108	26.53	8.68	0
	ALU		TISSUE	1194	0345	0103	28.89	8.63	0
	ACP	LI	DMN 90 UM/ML	0848	0574	0232	67.69	27.36	0
	ACP	LU	DMN 90 UM/ML	1111	0360	0127	32.40	11.43	0
000137406	ACT	LI1	0005-0 PCT.	0954	0275	0088	28.83	9.22	0
000137406	ACT	LI2	0025-1 PCT.	0994	0273	0068	27.46	6.84	0
000137406	ACT	LI3	0125-2 PCT.	0928	0243	0076	26.19	8.19	0
000137406	ACT	LU1	0005-0 PCT.	1148	0280	0087	24.39	7.58	0
000137406	ACT	LU2	0025-1 PCT.	1164	0212	0096	18.21	8.25	0
000137406	ACT	LU3	0125-2 PCT.	1126	0258	0112	22.91	9.95	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104 PROJECT 02468
EXPERIMENT 627801 DETECTOR TA100 SPECIES SPRDAW/RAT DATE - 10/27/76

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		DMN 90 UM/ML	2500	0518	20.72	0
	A-C		SOLVENT	2288	0591	25.83	0
	ALI		TISSUE	2172	0683	31.45	0
	ALU		TISSUE	2008	0543	27.04	0
	ACP	LI	DMN 90 UM/ML	1419	0876	61.73	0
	ACP	LU	DMN 90 UM/ML	2254	0636	28.22	0
000137406	ACT	LI1	0025-1 PCT.	2230	0897	40.22	0
000137406	ACT	LI2	0125-2 PCT.	2282	0879	38.52	0
000137406	ACT	LI3	0625-3 PCT.	2434	0709	29.13	0
000137406	ACT	LU1	0025-1 PCT.	1338	0583	43.57	0
000137406	ACT	LU2	0125-2 PCT.	1482	0683	46.09	0
000137406	ACT	LU3	0625-3 PCT.	1944	0622	32.00	0

REPORT EXR33 LITTON RIONETICS MUTAGENIC ACTIVITY SYSTEM
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104 PROJECT 02468
EXPERIMENT 626701 DETECTOR 1A1535 SPECIES SPRDAW/RAT

DATE - 10/27/76

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		DMN 90 UM/ML	0909	0098	10.78	0
	A-C		SOLVENT	1063	0108	10.16	0
	ALI		TISSUE	0672	0091	13.54	0
	ALU		TISSUE	0823	0104	12.64	2
	ACP	LI	DMN 90 UM/ML	1272	3140	246.86	0
	ACP	LU	DMN 90 UM/ML	0687	0096	13.97	2
000137406	ACT	LI1	0025-1 PCT.	0775	0075	9.68	0
000137406	ACT	LI2	0125-2 PCT.	1328	0134	10.09	2
000137406	ACT	LI3	0625-3 PCT.	0821	0141	17.17	0
000137406	ACT	LU1	0025-1 PCT.	1434	0069	4.81	2
000137406	ACT	LU2	0125-2 PCT.	1286	0063	4.90	0
000137406	ACT	LU3	0625-3 PCT.	1288	0076	5.90	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104 PROJECT 02468
EXPERIMENT 629501 DETECTOR TA1537 SPECIES SPRDAW/RAT

DATE - 10/27/76

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		AMQ 333 UG/ML	0600	0025	4.17	0
	A-C		SOLVENT	0641	0017	2.65	0
	ALI		TISSUE	0669	0025	3.74	1
	ALU		TISSUE	0568	0012	2.11	0
	ACP	LI	AMQ 333 UG/ML	0200	0245	122.50	1
	ACP	LU	AMQ 333 UG/ML	0582	0008	1.37	2
000137406	ACT	LI1	0025-1 PCT.	0609	0019	3.12	0
000137406	ACT	LI2	0125-2 PCT.	0570	0018	3.16	0
000137406	ACT	LI3	0625-3 PCT.	0582	0019	3.26	0
000137406	ACT	LU1	0025-1 PCT.	0547	0013	2.38	1
000137406	ACT	LU2	0125-2 PCT.	0533	0017	3.19	1
000137406	ACT	LU3	0625-3 PCT.	0587	0016	2.73	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104 PROJECT 02468
EXPERIMENT 626505 DETECTOR TA1538 SPECIES SPRDAW/RAT

DATE - 10/27/76

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		ANTH 67 UG/ML	0427	0021	4.92	0
	A-C		SOLVENT	0486	0020	4.12	0
	ALI		TISSUE	0271	0050	18.45	0
	ALU		TISSUE	0374	0028	7.49	0
	ACP	LI	ANTH 67 UG/ML	0269	0588	218.59	0
	ACP	LU	ANTH 67 UG/ML	0250	0683	273.20	0
000137406	ACT	LI1	0025-1 PCT.	0208	0017	8.17	0
000137406	ACT	LI2	0125-2 PCT.	0193	0025	12.95	0
000137406	ACT	LI3	0625-3 PCT.	0173	0029	16.76	0
000137406	ACT	LU1	0025-1 PCT.	0406	0018	4.43	0
000137406	ACT	LU2	0125-2 PCT.	0255	0031	12.16	2
000137406	ACT	LU3	0625-3 PCT.	0385	0052	13.51	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104 PROJECT 02468
EXPERIMENT 626502 DETECTOR TA98 SPECIES SPRDAW/RAT DATE - 10/27/76

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		ANTH 67 UG/ML	1712	0272	15.89	0
	A-C		SOLVENT	2147	0267	12.44	0
	ALI		TISSUE	2557	0297	11.62	0
	ALU		TISSUE	1650	0331	20.06	0
	ACP	LI	ANTH 67 UG/ML	1116	0938	84.05	0
	ACP	LU	ANTH 67 UG/ML	1304	0324	24.85	0
000137406	ACT	LI1	0025-1 PCT.	0827	0190	22.97	0
000137406	ACT	LI2	0125-2 PCT.	1034	0220	21.28	0
000137406	ACT	LI3	0625-3 PCT.	1005	0241	23.98	0
000137406	ACT	LU1	0025-1 PCT.	1058	0220	20.79	0
000137406	ACT	LU2	0125-2 PCT.	1247	0203	16.28	0
000137406	ACT	LU3	0625-3 PCT.	1512	0276	18.25	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
COMPOUND SUMMARY HACKUP DETAIL

CONTRACT 22374-2104 PROJECT 02468
EXPERIMENT 629502 DETECTOR 0000D4 SPECIES SPRDAW/RAT

DATE - 10/27/76

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+4	MUT1 EP+1	MUT2 EP+1	FREQ1 EP-5	FREQ2 EP-5	CONTAM
	A+C		DMN 90 UM/ML	0886	0381	0191	43.00	21.56	0
	A-C		SOLVENT	0761	0390	0155	51.25	20.37	0
	ALI		TISSUE	0708	0296	0187	41.81	26.41	0
	ALU		TISSUE	0726	0284	0153	39.12	21.07	0
	ACP	LI	DMN 90 UM/ML	0567	0453	0343	79.89	60.49	0
	ACP	LU	DMN 90 UM/ML	0826	0338	0186	40.92	22.52	0
000137406	ACT	LI1	0005-0 PCT.	0726	0358	0117	49.31	16.12	0
000137406	ACT	LI2	0025-1 PCT.	0641	0329	0127	51.33	19.81	0
000137406	ACT	LI3	0125-2 PCT.	0685	0288	0104	42.04	15.18	0
000137406	ACT	LU1	0005-0 PCT.	0593	0310	0083	52.28	14.00	0
000137406	ACT	LU2	0025-1 PCT.	0644	0283	0083	43.94	12.89	0
000137406	ACT	LU3	0125-2 PCT.	0613	0306	0093	49.92	15.17	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104		PROJECT 02468					
EXPERIMENT 627901	DETECTOR TA100	SPECIES RHESUS/MONKEY				DATE - 10/27/76	
COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		DMN 90 UM/ML	1736	0464	26.73	0
	A-C		SOLVENT	1842	0476	25.84	0
	ALI		TISSUE	2708	0814	30.06	0
	ALU		TISSUE	2442	0699	28.62	0
	ACP	LI	DMN 90 UM/ML	1184	0713	60.22	0
	ACP	LU	DMN 90 UM/ML	2430	0752	30.95	0
000137406	ACT	LI1	0025-1 PCT.	1590	0678	42.64	0
000137406	ACT	LI2	0125-2 PCT.	1852	0639	34.50	0
000137406	ACT	LI3	0625-3 PCT.	1976	0579	29.30	0
000137406	ACT	LU1	0025-1 PCT.	1504	0651	43.28	0
000137406	ACT	LU2	0125-2 PCT.	2018	0548	27.16	0
000137406	ACT	LU3	0625-3 PCT.	2458	0813	33.08	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104 PROJECT 02468
EXPERIMENT 628001 DETECTOR TA1535 SPECIES RHESUS/MONKEY

DATE - 10/27/76

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		DMN 90 UM/ML	2201	0164	7.45	0
	A-C		SOLVENT	2313	0223	9.64	0
	ALI		TISSUE	2757	0190	6.89	0
	ALU		TISSUE	2683	0203	7.57	0
	ACP	L1	DMN 90 UM/ML	1754	1020	58.15	0
	ACP	LU	DMN 90 UM/ML	2777	0245	8.82	0
000137406	ACT	LI1	0025-1 PCT.	2714	0198	7.30	0
000137406	ACT	LI2	0125-2 PCT.	2653	0167	6.29	0
000137406	ACT	LI3	0625-3 PCT.	2506	0161	6.42	0
000137406	ACT	LU1	0025-1 PCT.	2502	0163	6.51	0
000137406	ACT	LU2	0125-2 PCT.	2581	0146	5.66	0
000137406	ACT	LU3	0625-3 PCT.	2532	0198	7.82	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104 PROJECT 02468
EXPERIMENT 629701 DETECTOR 1A1537 SPECIES RHESUS/MONKEY

DATE - 10/27/76

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		AMQ 333 UG/ML	2774	0327	11.79	2
	A-C		SOLVENT	1818	0145	7.98	2
	ALI		TISSUE	0981	0181	18.45	2
	ALU		TISSUE	0996	0221	22.19	2
	ACP	LI	AMQ 333 UG/ML	2119	0065	3.07	2
	ACP	LU	AMQ 333 UG/ML	2400	0315	13.13	2
000137406	ACT	LI1	0025-1 PCT.	1168	0170	14.55	0
000137406	ACT	LI2	0125-2 PCT.	1038	0220	21.19	0
000137406	ACT	LI3	0625-3 PCT.	1461	0231	15.81	0
000137406	ACT	LU1	0025-1 PCT.	1712	0259	15.13	0
000137406	ACT	LU2	0125-2 PCT.	1340	0264	19.70	0
000137406	ACT	LU3	0625-3 PCT.	1608	0265	16.48	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104 PROJECT 02468
EXPERIMENT 627104 DETECTOR TA1538 SPECIES RHESUS/MONKEY DATE - 10/27/76

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		ANTH 67 UG/ML	0544	0018	3.31	0
	A-C		SOLVENT	0306	0019	6.21	0
	ALI		TISSUE	0418	0045	10.77	0
	ALU		TISSUE	0554	0021	3.79	0
	ACP	LI	ANTH 67 UG/ML	0334	1940	580.84	0
	ACP	LU	ANTH 67 UG/ML	0674	0026	3.86	0
000137406	ACT	LI1	0025-1 PCT.	0129	0015	11.63	0
000137406	ACT	LI2	0125-2 PCT.	0191	0021	10.99	0
000137406	ACT	LI3	0625-3 PCT.	0134	0018	13.43	0
000137406	ACT	LU1	0025-1 PCT.	0255	0028	10.98	0
000137406	ACT	LU2	0125-2 PCT.	0223	0023	10.31	0
000137406	ACT	LU3	0625-3 PCT.	0169	0025	14.79	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104 PROJECT 02468
EXPERIMENT 627401 DETECTOR TA98 SPECIES RHESUS/MONKEY DATE - 10/27/76

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+6	MUT1 EP+0	FREQ1 EP-8	CONTAM
	A+C		ANTH 67 UG/ML	1559	0412	26.43	1
	A-C		SOLVENT	1803	0489	27.12	0
	ALI		TISSUE	0916	0518	56.55	0
	ALU		TISSUE	0753	0463	61.49	1
	ACP	LI	ANTH 67 UG/ML	1088	0963	88.51	1
	ACP	LU	ANTH 67 UG/ML	0953	0409	42.92	0
000137406	ACT	LI1	0025-1 PCT.	1047	0377	36.01	0
000137406	ACT	LI2	0125-2 PCT.	1395	0408	29.25	1
000137406	ACT	LI3	0625-3 PCT.	0973	0461	47.38	1
000137406	ACT	LU1	0025-1 PCT.	1681	0418	24.87	0
000137406	ACT	LU2	0125-2 PCT.	1666	0479	28.75	1
000137406	ACT	LU3	0625-3 PCT.	1764	0426	24.15	0

REPORT EXR33 LITTON BIONETICS MUTAGENIC ACTIVITY SYSTEM
COMPOUND SUMMARY BACKUP DETAIL

CONTRACT 22374-2104 PROJECT 02468
EXPERIMENT 629503 DETECTOR 000004 SPECIES RHESUS/MONKEY DATE - 10/27/76

COMPOUND	TEST	ORG ID	CONCENTRATION	POPU EP+4	MUT1 EP+1	MUT2 EP+1	FREQ1 EP-5	FREQ2 EP-5	CONTAM
	A+C		DMN 90 UM/ML	0787	0104	0059	13.21	7.50	0
	A-C		SOLVENT	0624	0101	0047	16.19	7.53	0
	ALI		TISSUE	0751	0118	0058	15.71	7.72	0
	ALU		TISSUE	0734	0064	0042	8.72	5.72	0
	ACP	LI	DMN 90 UM/ML	0721	0486	0177	67.41	24.55	0
	ACP	LU	DMN 90 UM/ML	0735	0095	0045	12.93	6.12	0
000137406	ACT	LI1	0005-0 PCT.	0775	0109	0052	14.06	6.71	0
000137406	ACT	LI2	0025-1 PCT.	0749	0117	0051	15.62	6.81	0
000137406	ACT	LI3	0125-2 PCT.	0833	0123	0049	14.77	5.88	0
000137406	ACT	LU1	0005-0 PCT.	0744	0103	0055	13.84	7.39	0
000137406	ACT	LU2	0025-1 PCT.	0769	0091	0043	11.83	5.59	0
000137406	ACT	LU3	0125-2 PCT.	0792	0093	0044	11.74	5.56	0